Rumored Buzz on GW3965 hydrochloride
All enrolled clients who received at least 1 dose of zosuquidar or placebo all through induction had been monitored to the prevalence of adverse occasions (439 patients, 219 on zosuquidar and 210 on placebo). The most common adverse occasions ended up relevant to the duration of prolonged and substantial myelosuppression as is expected with inducti